Rappta: Rappta Therapeutics enters global license agreement with SpringWorks for a preclinical firstinclass molecular glue targeting PP2A
Rappta Therapeutics (Rappta), focused on developing first─in─class anti─cancer drugs activating protein phosphatase 2A (PP2A), announces an exclusive global license agreement with SpringWorks Therapeutics
Read full article »
Rappta is a Finland-based biopharmaceutical company that develops and commercializes drugs for the treatment of cancer.
Read more